Charles Hurty - IShares Medical Independent Trustee
| IHI Etf | USD 60.35 0.05 0.08% |
Mr. Charles A. Hurty serves as an Independent Trustee of Ishares Dow Jones US Medical Devices Index Fund since 2005. He serves as Chairman of the Audit Committee of the Trust since 2006. Mr. Hurty has served as a Director of iShares, Inc. since 2005, Chairman of the Audit Committee of iShares, Inc. since 2006, a Director of iShares MSCI Russia Capped Index Fund, Inc. since 2010 and Chairman of the Audit Committee of iShares MSCI Russia Capped Index Fund, Inc. since 2010. In addition, Mr. Hurty serves as Director of the GMAM Absolute Return Strategy Fund since 2002, Director of the SkyBridge MultiAdviser Hedge Fund Portfolios LLC since 2002 and was a Director of the CSFB Alternative Investment Funds from 2005 to December 2009, when the funds were liquidated. Mr. Hurty was formerly a Partner at KPMG, LLP from 1968 to 2001
| Age | 72 |
| Tenure | 19 years |
| Issuer | iShares |
| Inception Date | 2006-05-01 |
| Benchmark | Dow Jones U.S. Select Medical Equipment Index |
| Entity Type | Regulated Investment Company |
| Asset Under Management | 4.92 Billion |
| Average Trading Valume | 478,081.5 |
| Asset Type | Equity |
| Category | Sector |
| Focus | Health Care |
| Market Concentration | Developed Markets |
Similar Fund Executives
| Showing other executives | One Year Return | ||
| Cecilia Herbert | iShares Healthcare ETF | 67 | |
| Madhav Rajan | iShares Expanded Tech Software | 52 | |
| Madhav Rajan | iShares Healthcare ETF | 52 | |
| Robert Silver | iShares Healthcare ETF | 57 | |
| Robert Kapito | iShares Pharmaceuticals ETF | 62 | |
| John Kerrigan | iShares Aerospace Defense | 60 | |
| Robert Silver | iShares Expanded Tech Software | 57 | |
| Robert Kapito | iShares Expanded Tech Software | 62 | |
| Robert Silver | iShares Pharmaceuticals ETF | 57 | |
| George Parker | iShares Aerospace Defense | 80 | |
| John Kerrigan | iShares Healthcare ETF | 60 | |
| Eilleen Clavere | iShares Expanded Tech Software | 60 | |
| Madhav Rajan | iShares Pharmaceuticals ETF | 52 | |
| John Martinez | iShares Aerospace Defense | 55 | |
| John Kerrigan | iShares Pharmaceuticals ETF | 60 | |
| Robert Silver | iShares Aerospace Defense | 57 | |
| John Martinez | iShares Healthcare ETF | 55 | |
| Robert Kapito | iShares Healthcare ETF | 62 | |
| Cecilia Herbert | iShares Pharmaceuticals ETF | 67 | |
| John Martinez | iShares Expanded Tech Software | 55 | |
| Eilleen Clavere | iShares Aerospace Defense | 60 | |
iShares Medical Devices Money Managers
| Geoffrey Flynn, Chief Operating Officer, Executive Vice President | ||
| Robert Silver, Independent Trustee | ||
| John Kerrigan, Independent Trustee | ||
| Madhav Rajan, Independent Trustee | ||
| Matt Tucker, Vice President | ||
| Cecilia Herbert, Independent Trustee | ||
| Michael Latham, President Trustee | ||
| Jack Gee, Chief Financial Officer, Treasurer | ||
| Charles Hurty, Independent Trustee | ||
| Eilleen Clavere, Secretary | ||
| George Parker, Independent Chairman of the Board of Trustees | ||
| John Martinez, Independent Trustee | ||
| Amy Schioldager, Executive Vice President | ||
| Robert Kapito, Trustee | ||
| Ira Shapiro, Vice President Chief Legal Officer |
IShares Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is IShares Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Price To Earning | 24.14 X | |||
| Price To Book | 3.03 X | |||
| Price To Sales | 3.38 X | |||
| Number Of Employees | 15 | |||
| Beta | 1.04 | |||
| Total Asset | 5.79 B | |||
| One Year Return | 22.20 % | |||
| Three Year Return | (2.00) % | |||
| Five Year Return | 7.50 % | |||
| Ten Year Return | 13.10 % |
Currently Active Assets on Macroaxis
When determining whether iShares Medical Devices offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IShares Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ishares Medical Devices Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Ishares Medical Devices Etf:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Medical Devices. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
The market value of iShares Medical Devices is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Medical's value that differs from its market value or its book value, called intrinsic value, which is IShares Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Medical's market value can be influenced by many factors that don't directly affect IShares Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.